Skip to content

Study · Observational study · n = 13 · 2026

6 results

Preliminary Real-World Experience with Semaglutide in Obese Patients with Type 2 Diabetes on Chronic Hemodialysis: A Multicenter Pilot Study.

Yugueros A, D'Marco L, Valero A, Vivó E, Martínez-Mas A, Calvé M, Alonso JC, Vizcaíno B, González-Moya M, Checa-Ros A, Sancho A, Molina P

Medicina (Kaunas, Lithuania)16 Feb 2026Cited by 2 (Europe PMC)

PMID41752784 (opens in a new tab)PMCIDPMC12942463 (opens in a new tab)DOI10.3390/medicina62020386 (opens in a new tab)PepBankPUB-41752784
Download PDFPubMedAsk about this study
Jump to 6 results

Summary

Background and Objectives: Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) that has demonstrated metabolic and weight benefits in diabetic and obese patients with chronic kidney disease (CKD) who are not on dialysis; however, evidence in the hemodialysis (HD) population is scarce. Weight control and body composition optimization are particularly challenging in HD because of fluid shifts and the risk of protein-energy wasting. Materials and Methods: This prospective, multicenter, real-world, uncontrolled observational pilot study explored the short-term safety and changes in anthropometric and body-composition parameters after semaglutide initiation in obese adults with type 2 diabetes mellitus (T2DM) undergoing chronic HD. Patients were assessed at baseline and at 3 and 6 months. The primary endpoint was the change in body mass index (BMI), dry weight, and fat mass assessed by bioimpedance spectroscopy (BIS). Results: Thirteen patients were included (10 male, 77%), with a median age of 61.9 years (IQR 55-69). Semaglutide was started at 0.25 mg/week and titrated up to 1 mg/week according to tolerance. Three patients (23.1%) experienced transient nausea that was resolved over time or after dose adjustment, without discontinuation. From baseline to month +6, BMI decreased by a median of 1.5 kg/m2 and dry weight by 5.0 kg, mainly driven by a median reduction in fat mass of 9 kg; lean tissue mass and serum albumin did not change significantly. Conclusions: In this small, uncontrolled exploratory study, semaglutide was generally well tolerated and was associated with short-term reductions in body weight and fat mass in obese patients with T2DM on HD. These findings are hypothesis-generating and require confirmation in larger controlled prospective studies to define safety and clinical benefit in this population.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In obese adults with type 2 diabetes on hemodialysis, BMI decreased by a median of 1.5 kg/m2 from baseline to month 6 after semaglutide initiation.

    In plain wordsIn people on dialysis with obesity and diabetes, body mass index fell by a median of 1.5 after six months of semaglutide. No control group.

    Peptide
    Semaglutide
    Outcome
    DecreaseBMI change from baseline to month 6
    Study

    n = 13

    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.25 mg/week titrated up to 1 mg/week · 6 monthsAs given in this study (human).

    Measurements

    BMI change
    −1.5 kg/m2
    median

    Source sentences

    Summary
    BMI decreased by a median of 1.5 kg/m2
    1 context sentence
    Summary · context
    This prospective, multicenter, real-world, uncontrolled observational pilot study explored the short-term safety and changes in anthropometric and body-composition parameters after semaglutide initiation in obese adults with type 2 diabetes mellitus (T2DM) undergoing chronic HD.
  2. 02HumanObservational studyEfficacy outcome

    In obese adults with type 2 diabetes on hemodialysis, dry weight decreased by a median of 5.0 kg from baseline to month 6 after semaglutide initiation.

    In plain wordsIn people on dialysis with obesity and diabetes, dry weight fell by a median of 5.0 kg after six months of semaglutide. No control group.

    Peptide
    Semaglutide
    Outcome
    DecreaseDry weight change from baseline to month 6
    Study

    n = 13

    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.25 mg/week titrated up to 1 mg/week · 6 monthsAs given in this study (human).

    Measurements

    dry weight change
    −5 kg
    median

    Source sentences

    Summary
    dry weight by 5.0 kg, mainly driven by a median reduction in fat mass of 9 kg; lean tissue mass and serum albumin did not change significantly.
    1 context sentence
    Summary · context
    This prospective, multicenter, real-world, uncontrolled observational pilot study explored the short-term safety and changes in anthropometric and body-composition parameters after semaglutide initiation in obese adults with type 2 diabetes mellitus (T2DM) undergoing chronic HD.
  3. 03HumanObservational studyEfficacy outcome

    In obese adults with type 2 diabetes on hemodialysis, fat mass fell by a median of 9 kg from baseline to month 6 after semaglutide initiation.

    In plain wordsIn people on dialysis with obesity and diabetes, fat mass fell by a median of 9 kg after six months of semaglutide. No control group.

    Peptide
    Semaglutide
    Outcome
    DecreaseFat mass change from baseline to month 6
    Study

    n = 13

    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.25 mg/week titrated up to 1 mg/week · 6 monthsAs given in this study (human).

    Measurements

    fat mass change
    −9 kg
    median

    Source sentences

    Summary
    mainly driven by a median reduction in fat mass of 9 kg; lean tissue mass and serum albumin did not change significantly.
    1 context sentence
    Summary · context
    This prospective, multicenter, real-world, uncontrolled observational pilot study explored the short-term safety and changes in anthropometric and body-composition parameters after semaglutide initiation in obese adults with type 2 diabetes mellitus (T2DM) undergoing chronic HD.
  4. 04HumanObservational studySafety outcome

    In obese adults with type 2 diabetes on hemodialysis, three patients experienced transient nausea after semaglutide initiation, without discontinuation.

    In plain wordsIn people on dialysis with obesity and diabetes, three had short-lived nausea on semaglutide and none stopped treatment.

    Peptide
    Semaglutide
    Outcome
    Not applicableTransient nausea
    Study

    n = 13

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    0.25 mg/week titrated up to 1 mg/week · 6 monthsAs given in this study (human).

    Measurements

    patients with nausea
    3 patients
    proportion
    23.1%

    Source sentences

    Summary
    Three patients (23.1%) experienced transient nausea that was resolved over time or after dose adjustment, without discontinuation.
    1 context sentence
    Summary · context
    This prospective, multicenter, real-world, uncontrolled observational pilot study explored the short-term safety and changes in anthropometric and body-composition parameters after semaglutide initiation in obese adults with type 2 diabetes mellitus (T2DM) undergoing chronic HD.
  5. 05HumanObservational studyEfficacy outcome

    In obese adults with type 2 diabetes on hemodialysis, lean tissue mass did not change significantly after semaglutide initiation.

    In plain wordsIn people on dialysis with obesity and diabetes, lean tissue mass did not change clearly on semaglutide, without a control group.

    Peptide
    Semaglutide
    Outcome
    No significant changeLean tissue mass change
    Study

    n = 13

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.25 mg/week titrated up to 1 mg/week · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    lean tissue mass and serum albumin did not change significantly.
    1 context sentence
    Summary · context
    This prospective, multicenter, real-world, uncontrolled observational pilot study explored the short-term safety and changes in anthropometric and body-composition parameters after semaglutide initiation in obese adults with type 2 diabetes mellitus (T2DM) undergoing chronic HD.
  6. 06HumanObservational studyEfficacy outcome

    In obese adults with type 2 diabetes on hemodialysis, serum albumin did not change significantly after semaglutide initiation.

    In plain wordsIn people on dialysis with obesity and diabetes, serum albumin did not change clearly on semaglutide, without a control group.

    Peptide
    Semaglutide
    Outcome
    No significant changeSerum albumin change
    Study

    n = 13

    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    0.25 mg/week titrated up to 1 mg/week · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    lean tissue mass and serum albumin did not change significantly.
    1 context sentence
    Summary · context
    This prospective, multicenter, real-world, uncontrolled observational pilot study explored the short-term safety and changes in anthropometric and body-composition parameters after semaglutide initiation in obese adults with type 2 diabetes mellitus (T2DM) undergoing chronic HD.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.